Such is the case of Orkambi®, approved by Federal Drug Administration (FDA) and European Medical Agency (EMA) in 2015 for adult CF patients and in 2018 for CF children aged 2 years and older, who are homozygous for the F508del-CFTR mutation (Boyle et al., 2014). This evidence concerns the gene CFTR and cystic fibrosis.